JMJesus Mendiola-Precoma

Jesus Mendiola-Precoma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jesus Mendiola-Precoma has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnóstico del uso e implementación de la realidad aumentada en la Escuela de Bachilleres de la Universidad Autónoma de Querétaro

    by Luis Alberto Soto Reyes, Alfredo Rodríguez Cruz, Rita Ochoa Cruz, Jesus Mendiola-Precoma, José Eduardo Rodríguez Guevara, Zulma Yunue Cajiga Yañez

    Hoy en día, en la educación, la tecnología de realidad aumentada es una herramienta con gran potencial debido a que permite a los docentes y al alumnado (hombres y mujeres) abordar de una manera más dinámica el tema de estudio, de tal forma que el objetivo de la presente investigación abarca el diagnóstico de la comprensión y uso de la realidad aumentada en una muestra de la población institucional de la Escuela de Bachilleres de la Universidad Autónoma de Querétaro. Los resultados sugieren que se tiene un mínimo conocimiento respecto a la implementación y gestión de esta tecnología como parte de las estrategias de enseñanza-aprendizaje, motivo por el cual esta herramienta, actualmente, tiene un escaso uso en el proceso de enseñanza. Con respecto a lo anterior, se propone la creación de entornos de aprendizaje que integren la realidad aumentada para así aspirar a aumentar la comprensión de los temas de estudio.


  • Open Access

    “Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson’s disease”

    by Alfredo Rodríguez-Cruz, Antonio Romo-Mancillas, Jesus Mendiola-Precoma, Jesica Esther Escobar-Cabrera, Guadalupe García-Alcocer, Laura Cristina Berumen


  • Open Access

    Therapies for Prevention and Treatment of Alzheimer’s Disease

    by J. Mendiola-Precoma, L. C. Berumen, K. Padilla, G. Garcia-Alcocer

    Alzheimer’s disease (AD) is the most common cause of dementia associated with a progressive neurodegenerative disorder, with a prevalence of 44 million people throughout the world in 2015, and this figure is estimated to double by 2050. This disease is characterized by blood-brain barrier disruption, oxidative stress, mitochondrial impairment, neuroinflammation, and hypometabolism; it is related to amyloid-βpeptide accumulation and tau hyperphosphorylation as well as a decrease in acetylcholine levels and a reduction of cerebral blood flow. Obesity is a major risk factor for AD, because it induces adipokine dysregulation, which consists of the release of the proinflammatory adipokines and decreased anti-inflammatory adipokines, among other processes. The pharmacological treatments for AD can be divided into two categories: symptomatic treatments such as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists and etiology-based treatments such as secretase inhibitors, amyloid binders, and tau therapies. Strategies for prevention of AD through nonpharmacological treatments are associated with lifestyle interventions such as exercise, mental challenges, and socialization as well as caloric restriction and a healthy diet. AD is an important health issue on which all people should be informed so that prevention strategies that minimize the risk of its development may be implemented.